Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phenprocoumon
- Development stage
- Phase 4
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Phenprocoumon is a long-acting oral anticoagulant and a coumarin derivative. It acts as a vitamin K antagonist by inhibiting the enzyme vitamin K epoxide reductase, which is necessary for the synthesis of coagulation factors II, VII, IX, and X. It is used for the prevention and treatment of thromboembolic disorders such as venous thrombosis, thromboembolism, and pulmonary embolism. The most common adverse effect is bleeding.
- Brand names
- MarcoumarMarcumarFalithrom
- Other names
- PhenprocoumalolPhenprocoumarolPhenprogrammaPhenylpropylhydroxycumarinumFencumarPhenprocumoneFenprocumonePhenprocoumonumFenprocoumona
02
Targets
VKORC1 (Vitamin K epoxide reductase complex subunit 1)
Beyond the preview
Go deeper on phenprocoumon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phenprocoumon.